Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Propranolol Hydrochloride in Kaposi Sarcoma: NCT06445166 Clinical Landscape Report 2026
16 October 2026
NCT06445166 clinical landscape for Kaposi Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Ovarian Cancer: NCT06437353 Clinical Landscape Report 2026
16 October 2026
NCT06437353 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tafasitamab-Cxix in Scleroderma, Diffuse: NCT06434363 Clinical Landscape Report 2026
16 October 2026
NCT06434363 clinical landscape for Scleroderma, Diffuse: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Enfortumab Vedotin-ejfv in Locally Advanced Bladder Carcinoma: NCT06434350 Clinical Landscape Report 2026
16 October 2026
NCT06434350 clinical landscape for Locally Advanced Bladder Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Anlotinib Dihydrochloride in Solid tumor: NCT06438783 Clinical Landscape Report 2026
16 October 2026
NCT06438783 clinical landscape for Solid tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-TM4SF1 ADC (Angiex) in Liver Cancer: NCT06440005 Clinical Landscape Report 2026
16 October 2026
NCT06440005 clinical landscape for Liver Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Diffuse Large B-Cell Lymphoma: NCT06441097 Clinical Landscape Report 2026
16 October 2026
NCT06441097 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lutetium (177Lu) edotreotide in SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor: NCT06441331 Clinical Landscape Report 2026
16 October 2026
NCT06441331 clinical landscape for SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor: endpoints, sponsor, phase, geography, readouts, asset context…
9 min read
PF-07329640 in MSS/pMMR/MSI-L Colorectal Carcinoma: NCT06448364 Clinical Landscape Report 2026
16 October 2026
NCT06448364 clinical landscape for MSS/pMMR/MSI-L Colorectal Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
Etoposide in Ewing Sarcoma: NCT06451302 Clinical Landscape Report 2026
16 October 2026
NCT06451302 clinical landscape for Ewing Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TQB3702 in Systemic Lupus Erythematosus: NCT06448273 Clinical Landscape Report 2026
16 October 2026
NCT06448273 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gemcitabine Hydrochloride in High grade B-cell lymphoma: NCT06447376 Clinical Landscape Report 2026
16 October 2026
NCT06447376 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.